A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetu ximab or Infusional 5-Fluorouracil (5- FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetu ximab With a Safety Lead-in of Encorafenib Binimetinib Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
